L. Seman

发表

Purification of the apolipoprotein B-67-containing low density lipoprotein particle and its affinity for the low density lipoprotein receptor.

F. Welty, F. T. Yen, L. Seman, 1995, Journal of lipid research.

Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension

J. Izzo, K. Ferdinand, J. George, 2019, Circulation.

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

J. Rosenstock, H. Woerle, S. Hantel, 2013, Diabetes, obesity & metabolism.

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Co-administration in Healthy Volunteers: A Randomised, Open-label, Crossover Study

H. Woerle, H. Woerle, M. Mattheus, 2012 .

Lipid lowering and weight reduction by home-delivered dietary modification in coronary heart disease patients taking statins.

E. Schaefer, M. Meydani, J. McNamara, 2001, The American journal of cardiology.

Lipoprotein(a), homocysteine, and remnantlike particles: emerging risk factors.

E. Schaefer, J. McNamara, L. Seman, 1999, Current opinion in cardiology.

Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial

B. Zinman, C. Wanner, J. Cleland, 2021, European journal of heart failure.

The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.

J. Ordovás, E. Schaefer, A. Sevanian, 2000, Atherosclerosis.

Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a).

W. C. Breckenridge, L. Seman, W. Breckenridge, 1986, Biochemistry and cell biology = Biochimie et biologie cellulaire.

The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings.

A. Lichtenstein, E. Schaefer, S. Lamon-Fava, 2005, Metabolism: clinical and experimental.

Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.

E. Schaefer, J. McNamara, J. Rubenstein, 2002, The American journal of cardiology.

Ascorbic acid supplementation does not lower plasma lipoprotein(a) concentrations.

E. Schaefer, P. Jacques, J. Jenner, 2000, Atherosclerosis.

Lipoprotein(a) and coronary heart disease.

P. Wilson, J. Ordovás, E. Schaefer, 1994, Chemistry and physics of lipids.

Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction.

E. Schaefer, J. McNamara, J. Jenner, 1994, Clinical chemistry.

Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease.

E. Schaefer, J. McNamara, P. K. Shah, 2001, The American journal of cardiology.

The linkage with apolipoprotein (a) in lipoprotein (a) modifies the immunochemical and functional properties of apolipoprotein B.

Y. Marcel, R. Milne, W. C. Breckenridge, 1988, Biochemistry.

Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study

L. Cupples, E. Schaefer, V. Bongard, 2011, Journal of Lipid Research.

Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study.

P. Wilson, J. Ordovás, W. Castelli, 1999, Clinical chemistry.

The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development

Stephen A. Williams, J. Wagner, C. Girman, 2009, Clinical pharmacology and therapeutics.

Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

T. Macgregor, H. Woerle, M. Gastonguay, 2014, British Journal of Clinical Pharmacology.

Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study.

P. Wilson, J. Ordovás, W. Castelli, 1996, JAMA.

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.

E. Schaefer, J. McNamara, B. Asztalos, 2005, The American journal of cardiology.

Editorial: Beyond the Step I and II Diets: New Approaches to Managing Serum Cholesterol

L. Seman, 2000 .

Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry

G. Fonarow, S. Arnold, Philip G. Jones, 2020, Cardiovascular Diabetology.

A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

E. Ferrannini, H. Woerle, S. Hantel, 2013, Diabetes, obesity & metabolism.

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

T. Heise, H. Woerle, S. Hantel, 2013, Diabetes, obesity & metabolism.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

T. Heise, P. Jones, H. Woerle, 2013, Diabetes Therapy.

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

K. Dugi, G. Nehmiz, L. Seman, 2013, Clinical pharmacology in drug development.

Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.

H. Woerle, A. Sarashina, S. Sesoko, 2013, Drug metabolism and pharmacokinetics.

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.

U. Broedl, H. Woerle, M. Mattheus, 2013, International journal of clinical pharmacology and therapeutics.

Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus

K. Lipska, S. Arnold, M. Kosiborod, 2018, Journal of the American Geriatrics Society.

EMPAGLIFLOZIN IMPROVES BLOOD PRESSURE AS WELL AS GLYCEMIC CONTROL IN AFRICAN AMERICAN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION: A 24-WEEK RANDOMIZED CONTROLLED TRIAL

K. Ferdinand, J. George, A. Salsali, 2018 .

Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus

K. Ferdinand, A. Salsali, L. Seman, 2018, Current medical research and opinion.

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

H. Woerle, A. Sarashina, A. Taniguchi, 2013, Journal of diabetes investigation.

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.

E. Schaefer, J. McNamara, J. Rubenstein, 2004, The American journal of cardiology.

Isolation and purification of serum lipoprotein (a) using lectin affinity.

J. Jenner, L. Seman, C. de Luca, 1998, Methods in molecular biology.

Impact of pre‐existing type 2 diabetes with and without cardiovascular disease on patients with COVID‐19

T. Power, C. Crowe, C. Nguyen, 2023, Diabetes, obesity & metabolism.

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

Marc R Gastonguay, Alexander Staab, Sreeraj Macha, 2013, Journal of clinical pharmacology.

Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers

H. Woerle, A. Unseld, L. Seman, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development

Stephen A. Williams, J. Wagner, C. Girman, 2009, Clinical pharmacology and therapeutics.